Who are ABT-493's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EXVIERA, Post-transplant Grazoprevir and Elbasvir, OBV/PTV/r and DSV, PTV/r/OBV/DSV, glecaprevir/pibrentasvir tablets, Zepatier plus Sofosbuvir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-493.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ABT-493 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT-493 (ABT-493) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Diseases.

phase 2 protease inhibitor NS3/4A protease Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ABT-493 (ABT-493) — AbbVie. ABT-493 is a protease inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABT-493 TARGET	ABT-493	AbbVie	phase 2	protease inhibitor	NS3/4A protease
EXVIERA	EXVIERA	HaEmek Medical Center, Israel	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS5B, NS3/4A protease
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
OBV/PTV/r and DSV	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase
PTV/r/OBV/DSV	PTV/r/OBV/DSV	National Taiwan University Hospital	marketed	HCV direct-acting antiviral combination	HCV NS3/4A protease, NS5A, NS5B polymerase
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
AbbVie · 1 drug in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class
R-Pharm · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-493 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-493. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing